Trump aims to make Ozempic cheaper – Novo Nordisk and Eli Lilly under pressure
Reading Time: 2 minutes
The stocks of pharmaceutical companies Novo Nordisk and Eli Lilly fell sharply on Thursday evening after US President Donald Trump announced that he wants to set the price for the diabetes and weight-loss drug Ozempic "much lower." In a speech at the White House, Trump stated, according to Bloomberg Law , that patients should pay around 150 USD per month for the medication. The current list price is about 1,000 USD per month. Market reacts nervously The announcement triggered a significant response in the stock market: Novo Nordisk (NYSE: NVO)...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
